Literature DB >> 25599323

Neoadjuvant therapy for localized pancreatic cancer: support is growing?

Douglas B Evans1, Paul S Ritch, Beth A Erickson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25599323     DOI: 10.1097/SLA.0000000000000996

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  4 in total

Review 1.  Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.

Authors:  Francesco A D'Angelo; Laura Antolino; Mara La Rocca; Niccolò Petrucciani; Paolo Magistri; Paolo Aurello; Giovanni Ramacciato
Journal:  Med Oncol       Date:  2016-02-17       Impact factor: 3.064

2.  Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma.

Authors:  Motokazu Sugimoto; Michael B Farnell; David M Nagorney; Michael L Kendrick; Mark J Truty; Rory L Smoot; Suresh T Chari; Michael R Moynagh; Gloria M Petersen; Rickey E Carter; Naoki Takahashi
Journal:  J Gastrointest Surg       Date:  2018-02-01       Impact factor: 3.452

3.  Meta-analyses of treatment standards for pancreatic cancer.

Authors:  Jun Gong; Richard Tuli; Arvind Shinde; Andrew E Hendifar
Journal:  Mol Clin Oncol       Date:  2015-12-18

Review 4.  A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology.

Authors:  Robert E Van Sciver; Michael P Lee; Caroline Dasom Lee; Alex C Lafever; Elizaveta Svyatova; Kevin Kanda; Amber L Colliver; Lauren L Siewertsz van Reesema; Angela M Tang-Tan; Vasilena Zheleva; Monicah N Bwayi; Minglei Bian; Rebecca L Schmidt; Lynn M Matrisian; Gloria M Petersen; Amy H Tang
Journal:  Cancers (Basel)       Date:  2018-05-14       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.